Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Sep;12(9):1718-1722.
doi: 10.1111/jdi.13526. Epub 2021 Mar 10.

Lifestyle changes as a result of COVID-19 containment measures: Bodyweight and glycemic control in patients with diabetes in the Japanese declaration of a state of emergency

Nagaaki Tanaka  1   2 , Yoshiyuki Hamamoto  1   2 , Yuri Kurotobi  2 , Yuji Yamasaki  1   2 , Susumu Nakatani  1   2 , Miho Matsubara  1   2 , Takuya Haraguchi  1   2 , Yuko Yamaguchi  1   2 , Kiyohiro Izumi  1   2 , Yuki Fujita  1   2 , Hitoshi Kuwata  1   2 , Takanori Hyo  2 , Yuichiro Yamada  1   2 , Takeshi Kurose  1   2 , Yutaka Seino  1   2
Affiliations
Observational Study

Lifestyle changes as a result of COVID-19 containment measures: Bodyweight and glycemic control in patients with diabetes in the Japanese declaration of a state of emergency

Nagaaki Tanaka et al. J Diabetes Investig. 2021 Sep.

Abstract

To clarify the association between lifestyle changes as a result of coronavirus disease 2019 containment measures and changes in metabolic and glycemic status in patients with diabetes, a cross-sectional, single-center, observation study was carried out. A self-reported questionnaire was provided to ascertain the frequency of various lifestyle activities before and after the coronavirus disease 2019 containment measures in Japan. Among 463 patients, change in glycated hemoglobin was significantly associated with change in bodyweight. After stratification by age 65 years, binary logistic regression analysis showed that increased frequency of snack eating increased bodyweight (odds ratio 1.709, P = 0.007) and glycated hemoglobin (odds ratio 1.420, P = 0.025) in the younger group, whereas in the older patients, reduced walking activities resulted in weight gain (odds ratio 0.726, P = 0.010). In conclusion, changes in eating behavior and physical activity increased bodyweight and reduced glycemic control among diabetes patients, but by different processes depending on age under the coronavirus disease 2019 containment measures in Japan.

Keywords: COVID-19; Eating behavior; Physical activity.

PubMed Disclaimer

Conflict of interest statement

N Tanaka received speaker fees from Taisho Pharmaceutical, Nippon Becton‐Dickinson Co. Ltd. and Terumo. Y Hamamoto received speaker fees from Novo Nordisk Pharma Ltd., and also received research grants from Sumitomo‐Dainippon Pharma Co. Ltd. and Nippon Boehringer Ingelheim. H Kuwata received research grants from Taisho Pharmaceutical Co. Ltd, Novo Nordisk Pharma and Ono Pharmaceutical Co. Ltd. T Hyo received consulting or speaker fees from Arklay, AstraZeneca, Kissei Pharmaceutical, LifeScan Japan, Medtronic Japan, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Sanofi and Terumo. Y Yamada received consulting or speaker fees from MSD, Novo Nordisk Pharma, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Sanofi, Daiichi Sankyo and Mitsubishi Tanabe Pharma. Y Yamada also received clinically commissioned/joint research grants from Novo Nordisk Pharma, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Daiichi Sankyo and Mitsubishi Tanabe Pharma. T Kurose received speaker fees from Taisho Pharmaceutical and Ono Pharmaceutical. Y Seino received consulting or speaker fees from Eli Lilly Japan, Sanofi, Novo Nordisk Pharma, GlaxoSmithKline, Taisho Pharmaceutical, Taisho Pharmaceutical, Astellas Pharma, BD, Nippon Boehringer Ingelheim, Johnson & Johnson and Takeda Pharmaceutical. Y Seino also received clinically commissioned/joint research grants from Nippon Boehringer Ingelheim, Eli Lilly, Taisho Pharmaceutical, MSD, Ono Pharmaceutical, Novo Nordisk Pharma, Arklay and Terumo. Y Kurotobi, Y Yamasaki, S Nakatani, M Matsubara, T Haraguchi, Y Yamaguchi, K Izumi and Y Fujita declare no conflict of interest.

Figures

Figure 1
Figure 1
The association between quartiles of percentage change in bodyweight (%BW) and change in glycated hemoglobin (HbA1c) during the declaration of a state of emergency among patients with diabetes is shown. Values are the mean ± standard error. The median bodyweight change (interquartile range [IQR]) from quartile 1, 2, 3 and 4 was −3.63 (2.67), −1.16 (0.95), 0.00 (0.42) and 1.91 (1.82), respectively. *P < 0.05.
See this image and copyright information in PMC

References

    1. Shi Q, Zhang X, Jiang F, et al. Clinical characteristics and risk factors for mortality of COVID‐19 patients with diabetes in Wuhan, China: a two‐center retrospective study. Diabetes Care 2020; 43: 1382–1391. - PubMed
    1. Hwang Y, Khasag A, Jia W, et al. Diabetes and COVID‐19: IDF perspective in the Western Pacific region. Diabetes Res Clin Pract 2020; 166: 108278. - PMC - PubMed
    1. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382: 929–936. - PMC - PubMed
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. - PMC - PubMed
    1. Cabinet Secretariat Government of Japan . Basic Policies for Novel Coronavirus Disease Control by the Government of Japan (Summary) March 28, 2020 (Revised on May 25, 2020).

Publication types

MeSH terms